CHICAGO I just returned from New York City, which was the site of the Piper Jaffray Healthcare Conference. It was held from Tuesday to Thursday last week. The significance of this conference is:
It is the first
of 2004s east coast-based healthcare conferences. Remember that we started off the year with the JP Morgan Chase H&Q Healthcare Conference in San Francisco abo......Full article >>>
ext 20 years, the company would further intensify its position in the Midwest and the Great Plains states as a presence was acquired via the acquisition of another securities firm Jamieson & Company in 1964.
With this acquisition and further expansion, the company now had a presence in Billings, Mon.; Rochester, Minn.; Fargo, Grand Forks and Minot, N.D.; Duluth, Minn.; Sioux Falls, S.D......Full article >>>
ing and analyst teams in the U.S.
The Piper Jaffray Healthcare Conference was a four-track extravaganza featuring more than 160 healthcare companies large and small in the medical device, biotech and pharmaceuticals. Unlike its west coast counterpart (the H&Q meeting), this was not a mobbed meeting because it was held in a very exclusive, elegant and smallish hotel right in front of Cent......Full article >>>
e generic ANDA pathway basically applies to drugs for which a patent is about to expire or has expired and allows a company to use all data (safety and efficacy) already filed with the FDA by the innovator company and complete minimal drug development data (mostly bioequivalence data).
Under an ANDA scenario, the first generic company to file an ANDA for a generic drug and get FDA approv......Full article >>>
ive years for an NCE and seven years under orphan drug designation. While this is not of great interest to Big Pharma because market exclusivity is too short, it is of great interest to the specialty pharma industry.
Midwest companies were fairly well represented at this conference (as is appropriate given Piper Jaffrays origins). Those that presented at the conference included:
Full article >>>
e FDA of much of its diagnostics business and the recent hire of a senior consumer products executive from Wrigley to revamp its profitable but lackluster Ross nutritional business.
Unfortunately, the story spin was far too detailed and didnt present the excitement of whats to come in the future.
MGI Pharmas story was very much to the point and exciting. You can see why this co......Full article >>>
drugs in development (of which five have been approved and not yet launched).
21 cancer drugs are under actual FDA review.
67 cancer drugs are in phase III trials.
219 drugs are in phase II trials.
196 drugs are in phase I trials.
837 drugs are in pre-clinical development.
Another startling piece of information is......Full article >>>
ted last week with the successful IPO of Eyetech Pharmaceuticals, a New York-based ophthalmology biotech company. According to Monday mornings Wall Street Journal, the Eyetech IPO was strong enough that underwriters Merrill Lynch and Morgan Stanley were able to price the deal higher than anticipated ($21 a share versus prior estimates of $18 to $20 a share).
Eyetech shares ended up 54 pe......Full article >>>
Source:wistechnology.com By Michael Rosen 02/02/04Related biology technology :1
. Midwest life science stocks kept sizzling in Q22
. Midwest life science stocks sizzle in a tepid first quarter3
. A Midwest passage to India, Part II4
. Midwest offers non-stop flight to North Carolina research park5
. A Midwest life-science odyssey comes full circle6
. Midwest hotter for healthcare investments7
. A Midwest small-cap, life-science surprise package8
. 2006: A mixed blessing for Midwest life science companies9
. Midwest gaining stature in nanotech research10
. Midwest colleges strong contenders for NIH funds11
. Japan on the rebound: Implications for Midwest